## Laboratory Update





3/27/2014 - Immediate Action, Quest Diagnostics Nichols Institute, Valencia

TEST CHANGES  Please Note: Not all test codes assigned to each assay are listed in the table of contents.  Please refer to the complete listing on the page numbers indicated.						
Test Code	Former Test Code	Test Name	Effective Date	Page #		
16039		Mannose-binding Lectin (MBL)	3/27/2014	1		

SEND OUTS  Please Note: Not all test codes assigned to each assay are listed in the table of contents.  Please refer to the complete listing on the page numbers indicated.						
Test Code	Former Test Code	Test Name	Effective Date	Page #		
<u>\$50719</u>		14-3-3 Protein, CSF	3/31/2014	1		

Due to the background information related to these changes, we are unable to use our normal method of communication. These changes listed in this document are effective in less than 30 days. Please note the individual effective dates below, as some of these changes require IMMEDIATE ACTION.

## **Test Changes**

The following test changes will be effective on the dates indicated below. Please note that only the information that is changing appears in this update. Former test names and test codes have been italicized.

Mannose-binding Lectin (MBL)		
Effective Date	3/27/2014	
Test Code	16039	
Reject Criteria	Received room temperature; received refrigerated; hemolysis; lipemia; heat treated; specimens containing visible particulate matter	
Always Message	Mannan-binding lectin (MBL) is a serum collection (c-type lectin) and is considered an important component of the innate immune system. Clinical studies have used 50 or 100 ng/mL to define severe MBL deficiency. MBL is also known to activate the classical complement pathway through its binding to serine proteases MASP-2 and MASP-1. MBL deficiency has been associated with recurrent infections in children 6 months to 17 months of age, during the time when the adaptive immune system (IgG production) is not fully mature.  This test was performed using a kit that has not been approved or cleared by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics Nichols Institute, San Juan Capistrano. This test should not be used for diagnosis without confirmation by other medically established means.	
Assay Category	Research Use Only	
Performing Site	Quest Diagnostics Nichols Institute, San Juan Capistrano	

## **Test Send Outs (Referrals)**

Due to these assays being performed by outside vendors, we are unable to use our normal method of communication. Some of the changes listed in this document may be effective in less than 30 days. Please note the individual effective dates below, as these changes may require **IMMEDIATE ACTION.** 

14-3-3 Protein, CSF		
Effective Date	3/31/2014	

## 3/27/2014 - Immediate Action, Quest Diagnostics Nichols Institute, Valencia

Test Code	S50719			
CPT Codes	83520			
Always Message	These tests were developed and their performance characteristics determined by the NPDPSC. These tests have not been cleared or approved by the FDA. These assays should be used in conjunction with other clinical, pathological, and laboratory findings.			
Methodology	ELISA			
Assay Category	Laboratory Developed Assay			
CPU Mappings	S50719- 14-3-3 Protein  Result Code  107060  107737  This is a reflex. Please build this non-ord Reflex RT-QUIC  Result Code	Result Name  Result  Comments  derable unit code separately. A52602 –  Result Name		
	113832	Result		
Additional Information	If 14-3-3 protein is positive or tau is >or= 5 additional charge (CPT: 87999).	00 pg/mL, then A52602 Reflex RT-QUIC will b	e performed at an	